Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaEssentia's Beginning Cash Position for the quarter that ended in Mar. 2026 was NT$22,693 Mil.
PharmaEssentia's quarterly Beginning Cash Position
increased
from Sep. 2025 (NT$20,783 Mil) to Dec. 2025 (NT$21,581 Mil) and
increased
from Dec. 2025 (NT$21,581 Mil) to Mar. 2026 (NT$22,693 Mil).
PharmaEssentia's annual Beginning Cash Position
increased
from Dec. 2023 (NT$10,304 Mil) to Dec. 2024 (NT$19,666 Mil) and
increased
from Dec. 2024 (NT$19,666 Mil) to Dec. 2025 (NT$21,051 Mil).
PharmaEssentia Beginning Cash Position Related Terms
PharmaEssentia Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for PharmaEssentia's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Beginning Cash Position of NT$22,693 Mil mean?
PharmaEssentia (TPE:6446) has a Beginning Cash Position of NT$22,693 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PharmaEssentia and its competitors.
Is PharmaEssentia's Beginning Cash Position too high?
PharmaEssentia's current Beginning Cash Position is NT$22,693 Mil. Overall, PharmaEssentia has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PharmaEssentia's Beginning Cash Position compare to ZTS?
PharmaEssentia's Beginning Cash Position of NT$22,693 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PharmaEssentia and its competitors. PharmaEssentia's current Beginning Cash Position is NT$22,693 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEssentia stock overvalued right now?
Based on GuruFocus' analysis, PharmaEssentia (TPE:6446) is currently considered Fairly Valued. The stock's GF Value™ is NT$1,142.73, compared to a current price of NT$1,165.00 — trading 1.9% above its estimated fair value. The current Beginning Cash Position is NT$22,693 Mil. PharmaEssentia's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PharmaEssentia (TPE:6446), the current Beginning Cash Position is NT$22,693 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEssentia (TPE:6446) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEssentia stock appears to be overvalued.
The current stock price of NT$1,165.00 is trading 1.9% above its estimated GF Value™ of NT$1,142.73.
GuruFocus considers PharmaEssentia to be Fairly Valued.
Key valuation signals for TPE:6446:
Beginning Cash Position: NT$22,693 Mil
GF Value™: NT$1,142.73 vs. price of NT$1,165.00 (1.9% above fair value)
No single metric tells the full story. See the TPE:6446 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEssentia Corp engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API and new drug patterns developments. Its products include BESREMi, Ropeginterferon alfa-2b, Ropeg + anti PD-1, PEG-IL-2, PEG-Cytokines, PD-1-IL-2v, NY-ESO-1 TCR-T, among others. It derives revenue from medicine products sales from contracts with customers.
77GF Score
Get the complete analysis for TPE:6446
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6446 has been successfully added to your 
